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Context:Molecules that are released into biological ﬂuids during matrix metabolism of articular cartilage,
subchondral bone, and synovial tissue could serve as biochemical markers of the process of osteoarthritis
(OA). Unfortunately, actual breakthroughs in the biochemical OA marker ﬁeld are limited so far.
Objective: By reviewing the status of commercially available biochemical OA markers according to the
“Burden of disease, Investigative, Prognostic, Efﬁcacy of intervention, and Diagnostic” (“BIPED”) classi-
ﬁcation, future use of this “BIPED” classiﬁcation is encouraged and more efﬁcient biochemical OA marker
research stimulated.
Data sources: Three electronic databases [PubMed, Scopus, EMBASE (1997eMay 2009)] were searched for
publications on blood and urinary biochemical markers in human primary knee and hip-OA.
Study selection: Stepwise selection of original English publications describing human studies on blood or
urinary biochemical markers in primary knee or hip-OA was performed. Selected articles were fully read
to determine whether biochemical markers were investigated on performance within any of the “BIPED”
categories. Eighty-four relevant publications were identiﬁed.
Data extraction: Data from relevant publications were tabulated according to the “BIPED” classiﬁcation.
Individual analyses within a publication were summarized in general “BIPED” scores.
Data synthesis: An uneven distribution of scores on biochemical marker performance and heterogeneity
among the publications complicated direct comparison of individual biochemical markers. Comparison
of categories of biochemical markers was therefore performed instead. In general, biochemical markers
of cartilage degradation were investigated most extensively and performed well in comparison with
other categories of biochemical markers. Biochemical markers of bone metabolism performed less
adequately. Biochemical markers of synovial tissue metabolism were not investigated extensively, but
performed quite well.
Conclusions: Speciﬁc biochemical markers and categories of biochemical markers as well as their nature,
origin and metabolism, need further investigation. International standardization of future investigations
should be pursued to obtain more high-quality, homogenous data on the full spectrum of biochemical OA
markers.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a slowly progressive degenerative joint
disease that is traditionally associated with radiographic signs of: W.E. van Spil, Department
ity Medical Center Utrecht,
: 31-88-7557357; Fax: 31-30-
an Spil).
.
s Research Society International. Pjoint space narrowing, osteophyte formation, and subchondral
sclerosis. Its main clinical symptoms are variable joint pain and
stiffness, and occasional effusion. However, radiographic signs and
clinical symptoms only develop in late-stage OA when signiﬁcant
joint damage has already occurred1e4.
Development of disease modifying treatment modalities for OA
is challenging; lack of in-depth understanding of disease patho-
genesis, the slowly progressive character of OA, the insensitivity of
monitoring methods, and the limited relation between pain,
disability and structural changes, still necessitate long and large-
scale therapeutic trials. Therefore, current treatment strategies areublished by Elsevier Ltd. All rights reserved.
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procedures.
Biomarkers are deﬁned as characteristics that are objectively
measured and evaluated as indicators of normal biological
processes, pathogenic processes, or pharmacologic responses to
therapeutic interventions5. A lot of effort has been put into devel-
opment of biochemical markers that can aid diagnosing early-stage
OA, predicting OA progression, and assessing therapeutic response.
The availability of such biochemical markers could dramatically
improve diagnosis and treatment of OA.
With this in mind, numerous research groups study a plethora
of potential biochemical markers of joint metabolism and/or
disease: molecules or molecular fragments that are released into
biological ﬂuids from extracellular matrix turnover and/or cellular
metabolism of articular cartilage, subchondral bone and synovial
tissue. Although the rationale behind biochemical markers seems
so clear, breakthroughs in the biochemical marker ﬁeld are limited
so far and some authors now even doubt future applicability of
biochemical markers for OA6.
In 2006, Bauer et al. proposed the “BIPED” biomarker classiﬁ-
cation, in which the acronym “BIPED” stands for Burden of disease,
Investigative, Prognostic, Efﬁcacy of intervention, and Diagnostic7.
According to this classiﬁcation, each biochemical marker can be
classiﬁed to one or more of these categories. However, since its
introduction, the classiﬁcation has hardly been used. This is
unfortunate, because widespread use of a proper classiﬁcation
would enhance clear communication and contribute to organiza-
tion of current knowledge.
Therefore, this systematic review aims to assess the current
status of commercially available biochemical markers for each of
the “BIPED” classiﬁcation categories. This initiative might
encourage future widespread use of this classiﬁcation. Additionally,
by evaluating the thus far performed study designs and their
results, it contributes to development of directions for future study
designs.
Method
Three electronic databases were searched for relevant publica-
tions: PubMed, Scopus, and EMBASE. Key words in these searches
were as follows: OA/osteoarthrosis/arthrosis, knee/hip, biomarkers/
biological markers/biochemical markers, and blood/serum/plasma/
urine. The search was limited to urinary and blood biochemical
markers, since these are the most relevant biochemical markers
for clinical practice. Also, the search was limited to primary
knee andhip-OA, both frequent and invalidating forms of peripheral
OA.
Selection of publications was performed stepwise. First of all,
publications needed to be published in English, between 1st
January 1997 and 1st May 2009, and contain original data. Then,
one of the authors (WvS) identiﬁed relevant publications by
screening titles and abstracts for publications on human subjects,
primary knee and/or hip-OA (publications on explicit secondary
OA, e.g., after cruciate ligament rupture, were excluded), blood or
urinary biochemical marker concentrations, and biochemical
markers of matrix metabolism. Identiﬁed publications were then
completely read and evaluated for biochemical marker application
according to any of the “BIPED” categories.
Individual analyses of biochemical marker performance within
any of the “BIPED” categories were extracted from these publica-
tions. Thus, each publication could contain one or more of these
analyses; e.g., for knee and/or hip-OA, for several biochemical
markers, for several “BIPED” categories, and/or for several param-
eters within a “BIPED” category. Analyses of biochemical marker
performance within the “BIPED” categories were scored as follows:e Diagnostic: biochemical marker concentrations were statis-
tically signiﬁcantly different between patient and control
populations (tabulated as ‘þ’);
e Burden of disease: biochemical marker concentrations
differed statistically signiﬁcantly between patient pop-
ulations with different disease severity (discrete; tabulated as
‘þ’) or biochemical marker concentrations correlated signif-
icantly with parameters of disease severity (continuous;
tabulated as ‘þþ’);
e Prognostic: biochemical marker concentrations differed
statistically signiﬁcantly between patient populations with
progressive and non-progressive OA or between participants
that did and did not develop incident OA during follow-up
(discrete; both tabulated as ‘þ’), or biochemical marker
concentrations correlated signiﬁcantly with progression of
parameters of disease severity during follow-up (continuous;
tabulated as ‘þþ’);
e Efﬁcacy of intervention: biochemical marker concentrations
differed statistically signiﬁcantly between patient pop-
ulations with and without treatment, or before and after
treatment within patients (discrete; both tabulated as ‘þ’).
Importantly, publications on the biochemical marker
concentrations after arthroplastic surgery were not included.
e Investigative: biochemical markers in this category fell
outside the scope of this review and were therefore not
included.
Note that results that were not statistically signiﬁcant were
scored ‘’ for respective “BIPED” categories. Signiﬁcance was
strictly deﬁned as P< 0.05. Remarkably, several publications
handled this deﬁnition with more ﬂexibility when discussing
their results, and as such suggest relevant differences that are not
supported by their statistical data evaluation. For all analyses, it
was attempted to tabulate the most relevant score. For example,
when a statistically signiﬁcant difference of biochemical marker
concentrations between patients and controls became insigniﬁ-
cant after adjusting for age and body mass index (BMI), the
diagnostic capability of that biochemical marker was scored
negative (i.e., ‘’). Likewise, when biochemical marker concen-
trations correlated signiﬁcantly with disease parameters in
univariate analyses but not anymore after multivariate analyses,
the correlation was scored negative.
All analyses of biochemical marker performance in relation to
the “BIPED” categories were summarized in separate tables for
knee and hip-OA (Tables 1 and 2, Supplementary Tables). Each table
consists of six panels; cartilage synthesis, cartilage degradation,
bone synthesis, bone degradation, synovial tissue synthesis/
anabolic activity, and synovial tissue degradation/catabolic activity,
primarily based on the review by Garnero et al.8. It is important to
realize that this categorization is mainly hypothetical and that
actually little is known about the systemic origin andmetabolism of
many of the biochemical markers. In most cases the exact nature of
the molecular entities being measured is open to debate. General
study characteristics are depicted in the left part of the tables.
General scores for biochemical marker performancewithin “BIPED”
categories (/þ) are depicted in themiddle part of the tables.When
a biochemical marker scored ‘þ’ or ‘þþ’ for any of the individual
analyses within one “BIPED” category, the general score for that
“BIPED” category is ‘þ’. When a biochemical marker scored ‘’ for
all individual analyses within a “BIPED” category, the general score
for that “BIPED” category was ‘’. When no individual analyses
were applicable to one of the “BIPED” categories, that “BIPED”
category was not scored. These general “BIPED” scores were
considered most representative of biochemical marker perfor-
mance, and were used for calculations afterwards and referred to in
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ground of the general “BIPED” scores, the aforementioned indi-
vidual analyses from the original publications and their outcomes
are also provided, in the right part of the tables. Finally, the number
of general “BIPED” scores per biochemical marker and per category
of biochemical markers and the percentage of positive scores were
summarized in Table I.
Data extraction and tabulation were performed by one author
(WvS) and veriﬁed by at least one of the other authors (FL, JDG,
WL). Different interpretations between authors were discussed
until consensus was achieved.
Results
General
The database searches resulted in retrieval of 899 publications.
Figure 1 describes the subsequent selection of 84 relevant
publications.
A total of 428 general “BIPED” scores were extracted from these
publications. Of these scores, 331 (77%) concerned biochemical
marker performance in knee-OA, while 97 (23%) concerned hip-OA.
Biochemical markers of collagen metabolism gained most
attention. Of all 26 identiﬁed biochemical markers, 15 concerned
collagen metabolism. Eight biochemical markers concerned
collagen type II degradation (CTX-II, HELIX-II, C2C, Coll 2-1, Coll 2-1
NO (2), TIINE) and synthesis (PIIANP, PIICP), ﬁve concerned collagen
type I degradation (NTX-I, CTX-I, ICTP) and synthesis (PICP, PINP),
one concerned collagen type I and II degradation (C1, 2C) and one
concerned collagen type III synthesis (PIIINP). Among these
biochemical markers, urinary CTX-II (uCTX-II) was investigated
most extensively; 66 times in total. Collagen crosslinks [pyridinoline
(Pyr), deoxypyridinoline (D-Pyr), glucosyl-galactosyl pyridinoline
(Glc-Gal-Pyr)], non-collagenous proteins of cartilage [cartilage
oligomeric matrix protein (COMP), YKL-40] and bone [osteocalcin
(OC), bone sialoprotein (BSP)], glycosaminoglycans [hyaluronic acid
(HA), keratan sulphate (KS), chondroitin sulphate 846 (CS846)], and
pentosidinewere theotherbiochemicalmarkers that are considered
biochemical markers of matrix metabolism. Of these, serum COMP
(sCOMP) and sHA were scored relatively often in comparison with
the other biochemical markers: 57 and 45 times, respectively. All
other biomarkerswere scored less frequently;mostwere scored one
or two times per “BIPED” category. This limited number of scores for
the majority of individual biochemical markers necessitated anal-
ysis per biochemical marker category (synthesis/degradation,
articular cartilage/subchondral bone/synovial tissue) for compari-
sons instead of individual biochemical markers.
Information on the molecular basis of most biochemical
markers is described in the comprehensive review by Garnero et al.
in 20008 or more recent literature9e14. Note that Eyre et al. recently
reported their doubts about the origin of HELIX-II epitopes. They
showed that the HELIX-II epitope is not present on collagen type II,
but suggest its presence on collagen type III degradation products
instead15.
Diagnostic
The diagnostic applicability of serum and urinary biochemical
markers was scored 76 times (66 times for knee-OA and 10 times
for hip-OA) (Table I). Based on the number of studies, it was clear
that cartilage degradation is considered by many, the main and
central event in OA; biochemical markers of cartilage degradation
had been extensively investigated for their diagnostic applicability
in comparison with other biochemical marker categories. This
category performed quite adequately: for knee-OA, 26 of the 34investigations (76%) were scored positive. For hip-OA, all nine
reports (100%) scored positive. Although biochemical markers of
synovial tissue degradation received less attention (11 scores for
knee-OA, no scores for hip-OA), they appeared to perform consid-
erably well: nine out of the 11 scores (82%) were positive.
Biochemical markers of matrix synthesis were studied less than
those of matrix degradation in knee-OA, and not at all in hip-OA. On
the contrary, data on biochemical markers of bone degradation and
bone synthesis for diagnostic purposes were reported more evenly;
10 and eight reports, respectively. Explanations for this could be the
interest in the process of subchondral sclerosis and/or the avail-
ability of markers that were originally developed for bone diseases
such as osteoporosis. Biochemical markers of bone synthesis and
degradation performed somewhat less in diagnosing knee-OA than
biochemical markers of cartilage and synovial tissue metabolism;
ﬁve out of the nine reports (56%) on biochemical markers of bone
degradation, and three out of the eight reports (38%) on
biochemical markers of bone synthesis were scored positive.
Burden of disease
In total, serum and urinary biochemical marker concentrations
were investigated for correlations with parameters of burden of
disease 197 times (197 general “BIPED” scores). Again, biochemical
markers of matrix degradation were investigated more frequently
and performed better than those of matrix synthesis and
biochemical markers of bone metabolism performed less
adequately than those of cartilage metabolism. General perfor-
mance was somewhat lower than in the Diagnostic category.
Biochemical markers of cartilage degradation showed a signiﬁcant
correlation with structural and clinical parameters of burden of
disease in 35 of the 70 reports (50%) and 12 of the 26 reports (46%),
respectively. Biochemical markers of cartilage synthesis only
correlated signiﬁcantly with structural parameters of burden of
disease in four of 13 reports (31%) and clinical parameters in one of
ﬁve reports (20%). Biochemical markers of bone degradation scored
positive for relations with structural parameters of burden of
disease in nine out of 24 scores (38%), but did not score positive for
correlations with clinical parameters in any of nine scores (0%).
Biochemical markers of bone synthesis performed comparably
disappointingly; signiﬁcant correlations with structural parameters
of burden of disease in two out of 16 publications (13%), and with
clinical parameters of disease in two out of four publications (50%).
Also biochemical markers of synovial tissue metabolism/activity
performed less in the Burden of disease category than in the
Diagnostic category. For hip-OA, none of the ﬁve reports (0%) on
biochemical markers of synovial tissue metabolism and structural
and clinical parameters of burden of disease scored positive. For
biochemical markers of synovial tissue degradation in knee-OA, six
out of 15 scores (40%) and four out of eight scores (50%) were
positive for the relations with structural and clinical disease
parameters, respectively. The serum biochemical marker of syno-
vial tissue synthesis PIIINP was only scored twice.
The relative number of reports showing signiﬁcant relations
between biochemical markers of cartilage metabolism and
parameters of burden of disease did not differ between structural
and clinical parameters of burden of disease. The same applies to
biochemical markers of synovial tissue degradation and synthesis.
For biochemical markers of bone metabolism this is less clear (see
Table I).
Prognostic
Prognostic performance of biochemical markers in knee and
hip-OA was scored 126 times in total. Sixty-eight of these scores
Table I
Summary of the total number of general “BIPED” scores and percentage of positive “BIPED” scores for each biochemical marker and/or category of biochemical markers
Diagnostic Burden-struct Burden-clin Progn-struct Progn-clin Eff of interv Total /þ
Knee Hip Knee Hip Knee Hip Knee Hip Knee Hip Knee Hip
Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total /þ % þ Total  % þ Total  % þ Total /þ % þ
Cart degr 34 76% 9 100% 55 51% 15 47% 17 53% 9 33% 37 46% 11 73% 13 31% 7 43% 17 53% 0 0% 224
uCTX-II 9 89 4 100 13 77 5 80 6 17 1 100 12 75 5 80 3 67 3 67 5 80 66
uHELIX-II 1 100 1 100 1 100 1 100 1 100 5
uC1, 2C 1 0 1
uC2C 2 0 1 0 3
uColl 2-1 1 0 1 100 1 100 1 0 4
uColl 2-1
NO(2)
1 0 1 100 1 100 1 0 4
uTIINE 1 100 2 50 1 0 1 100 5
uPentosidine 1 0 1
sHELIX-II 1 0 1 0 2
sC1, 2C 2 50 2 0 2 0 3 0 1 0 1 0 11
sC2C 1 100 3 67 2 50 2 0 3 0 1 0 2 50 14
sColl 2-1 3 100 1 100 1 0 5
sColl 2-1
NO(2)
3 67 1 100 1 0 5
sCOMP 11 73 1 100 16 56 3 33 5 60 2 100 8 25 4 75 3 33 2 0 2 50 57
sKS 2 50 6 33 2 50 3 67 2 50 2 50 17
sPentosidine 2 100 1 0 1 100 4
sYKL-40 2 0 1 100 6 50 2 0 2 100 2 0 2 0 1 0 1 0 1 100 20
Cart synth 3 67% 0 NA 9 22% 4 50% 1 0% 4 25% 7 14% 0 NA 3 33% 0 NA 1 0% 0 NA 32
sPIIANP 2 100 3 33 1 0 2 50 1 100 1 0 10
sPIICP 3 0 2 100 2 50 3 0 1 0 11
sCS846 1 0 3 33 2 0 2 0 2 0 1 0 11
Bone degr 9 56% 1 0% 20 40% 4 25% 8 0% 1 0% 10 20% 5 40% 4 0% 4 25% 5 80% 0 NA 71
uCTX-I 2 50 3 33 1 0 1 0 1 0 1 100 1 0 1 0 11
uPYR 1 100 6 67 2 0 2 0 2 0 1 100 14
uD-PYR 1 100 1 0 4 50 1 0 2 0 2 0 1 0 2 0 1 0 1 100 16
uNTX-I 2 50 1 100 2 50 2 100 7
sNTX-I 2 50 1 0 3
sCTX-I 2 50 6 0 1 0 3 0 3 0 1 0 16
sICTP 1 0 1 100 l 100 1 100 4
Bone synth 8 38% 0 NA 11 9% 5 20% 2 50% 2 50% 4 50% 4 0% 1 0% 3 0% 2 50% 0 NA 42
sBSP 2 100 1 0 1 100 1 0 1 0 1 0 7
sOC 5 20 9 11 1 0 2 50 3 67 1 0 1 0 1 0 2 50 25
sPICP 1 0 1
sPINP 1 0 1 0 2 0 1 100 2 0 2 0 9
Syn degr 11 82% 0 NA 15 40% 2 0% 8 50% 1 0% 6 83% 1 100% 3 33% 1 100% 4 25% 0 NA 52
uGlc-Gal
-PYR
2 100 2 50 2 100 1 0 7
sHA 9 78 13 38 2 0 6 33 1 0 6 83 1 100 3 33 1 100 3 33 45
Syn synth 1 100% 0 NA 1 100% 1 0% 1 100% 1 0% 0 NA 1 0% 0 NA 1 0% 0 NA 0 NA 7
sPIIINP 1 100 1 100 1 0 1 100 1 0 1 0 1 0 7
Bone degr, bone degradation; bone synth, bone synthesis; cart degr, cartilage degradation; cart synth, cartilage synthesis; clin, clinical; eff of interv, efﬁcacy of intervention; struct, structural; syn degr, synovial tissue degradation
and/or activity; syn synth, synovial tissue synthesis.
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n= 91
Title and abstract Title and abstractTitle and abstract
Full article
EMBASE
15th May 2009 
n= 65 
n=  31
29 included
Full article
PubMed
15th May 2009 
n= 280 
76 included
Full article
Scopus
29th May 2009 
n= 554 
n= 48
44 included
BIPED ca 15 excl
Original article   10 excl
Human  2 excl
Hip/knee OA    119 excl
Blood/urine  12 excl
Matrix met  46 excl
English/Dutch 0 excl
Original article     7 excl
Human   0 excl
Hip/knee OA        6 excl
Blood/urine   3 excl
Matrix met  4 excl
English/Dutch    14 excl
BIPED cat  4 excl
Original article    90 excl
Human   127 excl
Hip/knee OA    208 excl
Blood/urine  51 excl
Matrix met    30 excl
English/Dutch 0 excl
Total: 84 included
BIPED cat  2 excl
Fig. 1. Flow diagram of the stepwise selection of relevant publications from initial search results. BIPED cat, “BIPED” category; excl, excluded; matrix met, matrix metabolite.
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Biochemical markers of cartilage degradation performed not so
well in predicting OA course; 25 out of 48 scores (52%) and seven
out of 20 scores (35%) were positive for relations between them and
structural and clinical OA progression, respectively. Biochemical
markers of cartilage synthesis were only investigated on their
relation with disease course for knee-OA. One out of seven scores
(14%) was positive for the relation between them and structural
progression, while one out of three scores (33%) was positive for
their relation with clinical progression.
Biochemical markers of bone metabolism had been moderately
investigated for their prognostic applicability in knee and hip-OA;
36 scores. Few publications reported positively on predicting
structural progression. Their performance in predicting clinical
progression was even worse: only one out of 12 scores (8%) was
positive for the relations between clinical progression of knee and
hip-OA and biochemical markers of bone metabolism.
Although biochemical markers of synovial tissue degradation
were scored only 11 times, they performed quitewell: ﬁve out of six
scores (83%) and one out of one score (100%) were positive for theirrelationship with structural progression of knee and hip-OA,
respectively. The same accounted for clinical progression: one out
of three scores (33%) showed signiﬁcant relations with clinical
progression of knee-OA, and one out of one (100%) showed this for
hip-OA. The only scores for performance of biochemical markers of
synovial tissue synthesis showed that sPIIINP concentrations did
not predict structural or clinical progression of hip-OA in a multi-
variate analysis.
Efﬁcacy of intervention
Twenty-nine scores for the relationships between biochemical
marker concentrations and interventions were evaluated. Seven-
teen reports on the relationship between interventions and
biochemical markers of cartilage degradation were found. Among
the biochemical markers of cartilage degradation, uCTX-II was the
most frequently studied biochemical marker. Four out of ﬁve scores
(80%) were positive for the change of uCTX-II concentration after
intervention. The publication not showing signiﬁcant changes of
uCTX-II concentrations was on intervention with chondroitin
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primary and secondary outcomes as well16. Another publication
failed to show efﬁcacy of oral risedronate on radiographic
progression, but showed signiﬁcant and dose-dependent changes
of uCTX-II concentrations17. Other biochemical marker categories
were scored less frequently and, surprisingly, biochemical markers
of synovial tissue synthesis were not scored at all.
Discussion
This review provides an overview of publications on biochem-
ical marker performance in primary knee and hip-OA and catego-
rizes their data according to the “BIPED” classiﬁcation. It is obvious
that biochemical markers of matrix degradation, and speciﬁcally
cartilage degradation, received much attention in comparison with
other biochemical marker categories. Biochemical markers of
matrix degradation performed better than those of matrix
synthesis. Biochemical markers of matrix synthesis are probably
most useful in combination with those of matrix degradation, as
has been demonstrated before3,18e20. Biochemical markers of bone
metabolism have been investigated to some extent, but their
performance was relatively disappointing. The contribution of
subchondral bone to systemic biochemical marker concentrations
may be obscured by the turnover of the complete skeleton.
Biochemical markers of synovial tissue metabolism have not (yet)
been investigated extensively, but available data looked promising,
suggesting involvement of synovial tissue in OA21. It is also clear
that biochemical markers have been more extensively investigated
in knee-OA than in hip-OA. Although complicated by this uneven
distribution, there is no obvious evidence that biochemical marker
performance is lower in hip-OA.
Overall, uCTX-II and sCOMP had the best performance of all
currently available commercial biochemical markers; they were
investigated most frequently and broadly, and scored in the higher
ranges of scores for most “BIPED” categories. However, this review
does not intend to suggest which of the investigated biochemical
markers intrinsically performs best, since the actual performance of
the majority of other serum and urinary biochemical markers
cannot be adequately evaluated as they were not that extensively
investigated as uCTX-II and sCOMP; most showed a maximum of
three general “BIPED” scores per “BIPED” category. Also the
observed heterogeneity among publications is a major compli-
cating factor in this respect. The majority of publications on less
frequently studied biochemical markers had an exploratory char-
acter with small-sized populations and/or applied a caseecontrol
design. Finally, comparison between biochemical markers is likely
to be complicated by publication bias; negative results will not
always be communicated. Especially in the Efﬁcacy of intervention
category this could be a major factor.
No consistent differences were observed between study
designs of those studies performing well for a certain biochemical
marker and those that did not. This was again complicated by the
uneven distribution of “BIPED” scores among biochemical
markers. Among the studies on more extensively investigated
biochemical markers, those on sCOMP seemed to perform some-
what less than those on uCTX-II within most “BIPED” categories.
This could be a non-relevant difference or may be due to selection
bias in the performed database search strategy, but may also be
due to differences in cohort and study design. Patient and control
populations of the publications on uCTX-II were frequently
obtained from population-based cohorts and clinical trials, while
populations of publications on sCOMP were frequently less well-
characterized. When participants are selected on tightly deﬁned
criteria, populations can be expected to be more homogeneous
and as such enable biochemical marker concentrations to showmore clear differences and/or correlations. Also, more publications
on uCTX-II paid special attention to sample collection methods
(e.g., fasting, second morning void urine) in comparison with
publications on sCOMP. It is suggested that standardization of
sample collection may improve biochemical marker performance,
since diurnal rhythms and inﬂuences of exercise have been
described for several biochemical markers22e26. Careful cohort
and study design could therefore explain part of the somewhat
better performance of uCTX-II.
The majority of scores for the cross-sectional and longitudinal
relationships between biochemical markers and disease parame-
ters concerned structural parameters rather than clinical parame-
ters. Structural disease was mainly deﬁned radiographically.
However, radiography is especially suited for visualization of bone
structures, while it can only indirectly visualize cartilage and
cannot visualize synovial tissue. Therefore, correlation of
biochemical markers of synovial tissue metabolism with radio-
graphic parameters can theoretically be expected to be minimal.
Additional observation of structural parameters by ultrasonog-
raphy, magnetic resonance imaging (MRI) or arthroscopy enables
more direct visualization of cartilage and synovial tissue and could
therefore lead to better and more representative correlations.
Wakitani et al. showed signiﬁcantly increased sKS and sCOMP
concentrations in knee-OA patients with radiographic signs of
Kellgren and Lawrence grade 0 but already showing arthroscopi-
cally visible cartilage lesions4. Garnero et al. demonstrated signif-
icantly different arthroscopically identiﬁed progression between
patients with high and low uCTX-II concentrations, but failed to
demonstrate differences in radiographic progression between
these patients18. Georges et al. showed signiﬁcantly different sHA
and sKS concentrations between arthroscopically deﬁned pro-
gressors and non-progressors after a 1-year follow-up27. They refer
to publications that show comparable results for sHA performance,
but that needed a 5-year radiographic follow-up. Correlations
between biochemical marker concentrations and ultrasonographic
parameters of cartilage and synovial tissue were reported28e30.
Furthermore, Kumm et al. reported on signiﬁcantly different
sCOMP concentrations between participants with and without
ultrasonographically observed meniscal changes29. These partici-
pants complained of chronic knee pain and/or other knee limita-
tions but did not always have radiographically detectable knee-OA.
MRI had been used to compose a whole organ MRI score that is
composed of cartilage, subchondral bone, synovial tissue and per-
iarticular tissue parameters in knee-OA31. Another feature that was
observed by MRI and had been correlated to biochemical marker
concentrations is the presence of bone marrow lesions in knee-
OA32e34. In the publications that were included in this review,
publications on sCOMP reported more heterogeneous disease
parameters than those on uCTX-II, and included ultrasonographic,
MRI and scintigraphic parameters. In contrast to the suggested
above, our scoring method was not clearly able to show an additive
value of these alternative approaches in supporting the applica-
bility of sCOMP in OA.
This review shows that there is a lack of consistent evidence for
the vast majority of commercially available biochemical markers.
This lack of interest for these less frequently studied biochemical
markers is not necessarily supported by publications showing
limited applicability. Additional investigation of these biochemical
markers in large-scale, cohort studies is crucial to increase our
knowledge about the applicability of these biochemical markers
and aid to our understanding of OA pathogenesis. Most biochemical
markers are still in an explorative stage and publication bias is
therefore undesirable and should be prevented. Also, this review
shows that our knowledge of applicability of biochemical markers
in hip-OA is limited in comparison with knee-OA. Additional
W.E. van Spil et al. / Osteoarthritis and Cartilage 18 (2010) 605e612 611investigation on hip-OA, and other types of OA, is therefore
encouraged.
Little is known about molecular validity, systemic origin and
metabolism of the majority of biochemical markers, and with that
implications of measured biochemical marker concentrations are
still open to debate. For example, Eyre et al. debated presence of the
HELIX-II epitope on collagen type II and suggested its presence on
collagen type III degradation products instead15. This lack of
knowledge of the molecular validity of biochemical markers and
systemic biochemical marker origins and metabolism forms
a major barrier in performing and interpreting clinical biochemical
marker studies. For example, Otterness et al. detected an
unexpected increase of uTIINE concentrations in doxycycline-
treated knee-OA patients and could only speculate about doxycy-
cline-induced changes of sTIINE metabolism35. As such, there is an
urgent need for investigation of the many unknowns about sources
and systemic metabolism of biochemical markers and correlation
with speciﬁc aspects of OA. Incorporation of methodologies that
were originally developed and demanded by regulatory authorities
to study pharmacokinetics of drugs (i.e., absorption, distribution,
metabolism and excretion) in biochemical marker characterization
would be useful in this respect. Knowledge of these aspects of
biochemical markers would contribute to adequate set-up of clin-
ical studies and proper interpretation of results thereof.
Comparison of biochemical marker performance is complicated
by the uneven distribution of biochemical marker performance
scores and heterogenic study design. Also, this heterogeneity
hampers pooling of data. International standards of study design
would increase homogeneity of data, and dramatically increase
quality and efﬁcacy of biochemical marker investigation and
thereby contribute to progression of the biochemical marker ﬁeld.Conclusion
None of the current biochemical markers is sufﬁciently
discriminating to aid to diagnosis and prognosis of OA in individual
or limited numbers of patients, or performs so consistently that it
could function as an outcome in clinical trials. Future research
should focus on molecular validation, origins and metabolism of
biochemical markers as well as on broad spectrum biochemical
marker analysis in well-deﬁned populations, with protocolized
sample collection. Most importantly, more research should be
aimed at clarifying themany unknowns about sources and systemic
metabolism of biomarkers and correlation with speciﬁc aspects of
the pathology, to bring the biomarker ﬁeld signiﬁcant steps
forward.
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